Evidence map›Paper›PMID 28428206›Full record

ReviewAJNR. American journal of neuroradiology2017

Current and Emerging Therapies in Multiple Sclerosis: Implications for the Radiologist, Part 2-Surveillance for Treatment Complications and Disease Progression.

C McNamara, G Sugrue, B Murray, P J MacMahon

Abstract readReview
In one paragraph

Review in AJNR. American journal of neuroradiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

C McNamaraFrom the Departments of Radiology (C.M., G.S., P.J.M.).ORCID http://orcid.org/0000-0001-8164-7794
G SugrueFrom the Departments of Radiology (C.M., G.S., P.J.M.).ORCID http://orcid.org/0000-0003-1159-5225
B MurrayNeurology (B.M.), Mater Misericordiae University Hospital, Dublin, Ireland.ORCID http://orcid.org/0000-0002-7089-1422
P J MacMahonFrom the Departments of Radiology (C.M., G.S., P.J.M.) pmacmahon@mater.ie.ORCID http://orcid.org/0000-0003-2235-6692

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An understanding of the new generation of MS drugs in conjunction with the key role MR imaging plays in the detection of disease progression, opportunistic infections, and drug-related adverse effects is of vital importance to the neuroradiologist. Part 1 of this review outlined the current treatment options available for MS and examined the mechanisms of action of the various medications. It also covered specific complications associated with each form of therapy. Part 2, in turn deals with the subject of pharmacovigilance and the optimal frequency of MRI monitoring for each individual patient, depending on his or her unique risk profile. Special attention is given to the diagnosing of progressive multifocal leukoencephalopathy in patients treated with natalizumab as this is a key area in which neuroradiologists can contribute to improved patient outcomes. This article also outlines the aims of treatment and reviews the possibility of "no evidence of disease activity" becoming a treatment goal with the availability of more effective therapies. Potential future areas and technologies including image subtraction, brain volume measurement and advanced imaging techniques such as double inversion recovery are also reviewed. It is anticipated that such advancements in this rapidly developing field will improve the accuracy of monitoring an individual patient's response to treatment.

Indexed as

RadiologistsAntibodies, Monoclonal, HumanizedHumansLeukoencephalopathy, Progressive MultifocalMultiple SclerosisNatalizumabTreatment OutcomeAntibodies, Monoclonal, HumanizedNatalizumab

Identifiers

PMID28428206
PMCPMC7963720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.